Bioethics News

Stem Cells for Personalized Pain Therapy Testing

April 22, 2016

(The Scientist) – Pain can be tough to take, and it’s also difficult to study: rodent models for pain do not necessarily translate to human pain conditions and expression of disease-causing mutations in cell lines may not precisely mimic the physiology of human pain disorders. Now, researchers have developed a new way to test pain—and, potentially, other sensory-targeting medications. Edward Stevens and James Bilsland of the Pfizer’s U.K.-based neuroscience and pain research units and their colleagues have shown that induced pluripotent stem cells (iPSCs) derived from blood samples of patients with a pain disorder can be used to create sensory neurons that recapitulate the disease phenotype.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.